



## EXTRAORDINARY GENERAL MEETING OF ARGENX SE EXPLANATORY NOTES

The following item on the agenda of the extraordinary general meeting of argenx SE (the "**Company**") shall be discussed and/or put to a vote. The number in the list correspond to the number on the agenda.

### **2. Appointment of Camilla Sylvest as non-executive director to the board of directors of the Company (voting item)**

The Board proposes to appoint Camilla Sylvest as a non-executive director of the Company with effect from the date of this extraordinary general meeting.

The proposed appointment is for a term ending on the day of the annual general meeting of shareholders to be held in 2026. The proposed appointment is in accordance with the Company's articles of association and takes into account the pursued composition and profile of the Board as apparent from the Company's profile for the non-executive directors which is available on the Company website.

In making this proposal, the Board has taken into consideration Camilla Sylvest's skills, knowledge and expertise built up during her career.

**Camilla Sylvest** (age 49) is the Executive Vice President, Commercial Strategy & Corporate Affairs of Novo Nordisk A/S. Camilla Sylvest has more than 25 years of working experience within Novo Nordisk and was based in Switzerland, Denmark, Germany, Malaysia and China. Over the years Camilla Sylvest headed up affiliates of growing size and complexity in Europe within Novo Nordisk and she was also Corporate VP Business Area Oceania and Southeast Asia (BAOS) and Senior Vice President and General Manager Novo Nordisk Region China. She also serves as the vice chair of the World Diabetes Foundation Board (WDF) and as a member of the Board in Danish Crown A/S. Camilla Sylvest holds a Master of Science in Economics from the University of Odense, Denmark and an Executive MBA from the Scandinavian Management Institute in Copenhagen, Denmark.

Camilla brings strong strategic and operational experience with the global commercial pharmaceuticals market place, with the global scaling of commercial organizations and brings a real passion for company culture, leadership and sustainability.

It is envisaged that Camilla will join the Commercialization Committee of the Board of Directors.

Camilla Sylvest holds no shares in argenx SE.